On the 11th (local time), the European Medicines Agency (EMA) recommended the approval of two types of antibody treatment for COVID-19 by Celltrion of Korea and Regeneron, a US pharmaceutical company.
On the same day, the EMA's Drug User Advisory Committee (CHMP) recommended that Celltrion's COVID-19 antibody treatment Regkirona be approved for use in the treatment of adults who are infected with COVID-19 and are at high risk of becoming severe.
The patient should be in a situation that does not require artificial respiration.
The CHMP also recommended that the US pharmaceutical company Regeneron's antibody treatment 'Ronapreve' be approved for use in the treatment of adolescents and adults 12 years of age or older who are at high risk of worsening from COVID-19 infection.
Lonapreve may be used to prevent COVID-19 in adults 12 years of age and older, CHMP added.
These two species are the first to recommend approval for monoclonal antibody therapy in Europe.
These antibody therapeutics will be put into treatment for the first time in Europe, where COVID-19 is spreading at the fastest rate ever.
The two companies applied for sales approval to the EMA in early October, and the EMA has promised to comment within two months.
Earlier, US pharmaceutical company Eli Lilly withdrew its conditional approval application to the EU last week, citing a lack of demand.